cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2566cardio-448Research ArticleОБЗОРЫREVIEWSАнтигипертензивная терапия у мужчин и женщин: существуют ли особенности в выборе лекарственных препаратов?Antihypertensive therapy in male and female: are there sex differences in choice of drugs?ЛаринаВ. Н.LarinaV. N.

117997, Москва, ул. Островитянова, д. 1

Ostrovityanova 1, Moscow 117997

ОрловД. А.OrlovD. A.

117997, Москва, ул. Островитянова, д. 1

Ostrovityanova 1, Moscow 117997

ФГБОУ ВО «РНИМУ им. Н. И. Пирогова» МЗ РФРоссияPirogov Russian National Research Medical UniversityRussian Federation201931012019591S1118Copyright © Kardiomag, 20192019KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/448

В обзорной статье представлены данные по распространенности, контролю и эффективности лечения АГ у мужчин и женщин. Обсуждаются особенности протективного действия и проявлений нежелательных эффектов антигипертензивной терапии у мужчин и женщин, а также ситуации, влияющие на выбор того или иного лекарственного препарата в зависимости от пола.

Tis review presents data on prevalence, control, and effectiveness of treatment of hypertension in male and female. Te features of protective action and manifestations of undesirable effects of antihypertensive therapy in male and female, as well as situations influencing the choice of a drug depending on sex are discussed.

артериальная гипертензиямужчиныженщиныантигипертензивная терапиягендерные различияhyperpiesismenwomenantihypertensive therapygender differencesReferencesDoumas M, Papademetriou V, Faselis C, Kokkinos P. Gender Differences in Hypertension: Myths and Reality. Current Hypertension Reports. 2013;15(4):321–30. DOI: 10.1007/s11906-013-0359-yDoumas M, Papademetriou V, Faselis C, Kokkinos P. Gender Differences in Hypertension: Myths and Reality. Current Hypertension Reports. 2013;15(4):321–30. DOI: 10.1007/s11906-013-0359-yPimenta E. Hypertension in women. Hypertension Research. 2012;35(2):148–52. DOI: 10.1038/hr.2011.190Pimenta E. Hypertension in women. Hypertension Research. 2012;35(2):148–52. DOI: 10.1038/hr.2011.190Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165. DOI: 10.1001/jama.2016.19043Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317(2):165. DOI: 10.1001/jama.2016.19043Wolf-Maier K. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. JAMA. 2003;289(18):2363. DOI: 10.1001/jama.289.18.2363Wolf-Maier K. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. JAMA. 2003;289(18):2363. DOI: 10.1001/jama.289.18.2363Бойцов С. А., Баланова Ю. А., Шальнова С. А., Деев А. Д., Артамонова Г. В., Гатагонова Т. М. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная Терапия И Профилактика. 2014;13(4):4–14.Boytsov S. A., Balanova Yu. A., Shalnova S. A., Deev A. D., Artamonova G. V., Gatagonova T. M. et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Terapy and Prevention. 2014;13(4):4-14.Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal. 2016;37(42):3232–45. DOI: 10.1093/eurheartj/ehw334Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. European Heart Journal. 2016;37(42):3232–45. DOI: 10.1093/eurheartj/ehw334Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L et al. Prehypertension and Cardiovascular Disease Risk in the Women’s Health Initiative. Circulation. 2007;115(7):855–60. DOI: 10.1161/CIRCULATIONAHA.106.656850Hsia J, Margolis KL, Eaton CB, Wenger NK, Allison M, Wu L et al. Prehypertension and Cardiovascular Disease Risk in the Women’s Health Initiative. Circulation. 2007;115(7):855–60. DOI: 10.1161/CIRCULATIONAHA.106.656850Nichols M, Townsend N, Scarborough P, Rayner M. European cardiovascular disease statistics. 128 p. ISBN 978-2-9537898-1-2Nichols M, Townsend N, Scarborough P, Rayner M. European cardiovascular disease statistics. 128 p. ISBN 978-2-9537898-1-2Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM et al. Heart Disease and Stroke Statistics—2011 Update: A Report from the American Heart Association. Circulation. 2011;123(4):e18– 209. DOI: 10.1161/CIR.0b013e3182009701Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM et al. Heart Disease and Stroke Statistics—2011 Update: A Report from the American Heart Association. Circulation. 2011;123(4):e18– 209. DOI: 10.1161/CIR.0b013e3182009701Чазова И. Е., Ощепкова Е. В. Итоги реализации Федеральной целевой программы по профилактике и лечению артериальной гипертензии в России в 2002-2012 гг. Вестник Российской академии медицинских наук. 2013;68(2):4–11. DOI: 10.15690/vramn.v68i2.542Chazova I. E., Oschepkova E. V. Results of the Federal (National) Project for prevention and treatment essential hypertension patients in Russia from 2002-2012 years. Annals of the Russian academy of medical sciences. 2013;68(2):4-11. DOI: 10.15690/vramn.v68i2.542Глезер М. Г., Карпов Ю. А. Программа ФОРТИССИМО: оценка эффективности и безопасности нолипрела а би-форте в лечении артериальной гипертонии у мужчин и женщин. Проблемы женского здоровья. 2013;8(3):5–15.Glezer M. G., Karpov Yu. A. Te program FORTISSIMO: evaluation of efcacy and safety Noliprel A B-forte in the treatment of hypertension of men and women. Women’s health problems. 2013;8(3):5-15.Katsi V, Kallistratos MS, Kontoangelos K, Sakkas P, Souliotis K, Tsioufs C et al. Arterial Hypertension and Health-Related Quality of Life. Frontiers in Psychiatry. 2017;8. DOI: 10.3389/fpsyt.2017.00270Katsi V, Kallistratos MS, Kontoangelos K, Sakkas P, Souliotis K, Tsioufs C et al. Arterial Hypertension and Health-Related Quality of Life. Frontiers in Psychiatry. 2017;8. DOI: 10.3389/fpsyt.2017.00270Гринштейн Ю. И., Петрова М. М., Шабалин В. В., Руф Р. Р., Баланова Ю. А., Евстифеева С. Е. et al. Распространенность артериальной гипертензии в Красноярском крае по данным эпидемиологического исследования ЭССЕ-РФ. Артериальная Гипертензия. 2016;22(6):551–9.Grinshtein Yu. I., Petrova M. M., Shabalin V. V., Ruf R. R., Balanova Yu. A., Evstifeeva S. E. et al. Te prevalence of arterial hypertension in krasnoyarsky territory: the data from the epidemiology study ESSE-RF. Arterial hypertension. 2016;22(6):551-9.Hajar R. Framingham contribution to cardiovascular disease. Heart Views. 2016;17(2):78. DOI: 10.4103/1995-705X.185130Hajar R. Framingham contribution to cardiovascular disease. Heart Views. 2016;17(2):78. DOI: 10.4103/1995-705X.185130Etehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Te Lancet. 2016;387(10022):957–67. DOI: 10.1016/S0140-6736(15)01225-8Etehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Te Lancet. 2016;387(10022):957–67. DOI: 10.1016/S0140-6736(15)01225-8Deborde T, Amar L, Bobrie G, Postel-Vinay N, Bataglia C, Tache A et al. Sex differences in antihypertensive treatment in France among 17 856 patients in a tertiary hypertension unit: Journal of Hypertension. 2018;36(4):939–46. DOI: 10.1097/HJH.0000000000001607Deborde T, Amar L, Bobrie G, Postel-Vinay N, Bataglia C, Tache A et al. Sex differences in antihypertensive treatment in France among 17 856 patients in a tertiary hypertension unit: Journal of Hypertension. 2018;36(4):939–46. DOI: 10.1097/HJH.0000000000001607Hansen TW, Kikuya M, Tijs L, Li Y, Boggia J, Björklund-Bodegârd K et al. Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis-clinical implications. Journal of Clinical Hypertension (Greenwich, Conn.). 2008;10(5):377–81. PMID: 18453797Hansen TW, Kikuya M, Tijs L, Li Y, Boggia J, Björklund-Bodegârd K et al. Diagnostic thresholds for ambulatory blood pressure moving lower: a review based on a meta-analysis-clinical implications. Journal of Clinical Hypertension (Greenwich, Conn.). 2008;10(5):377–81. PMID: 18453797Чазова И. Е., Фомин В. В., Разуваева М. А., Вигдорчик А. В. Эпидемиологическая характеристика резистентной и неконтролируемой артериальной гипертензии в Российской Федерации (Российский регистр неконтролируемой и резистентной артериальной гипертензии РЕГАТА-ПРИМА “РЕзистентная Гипертония АрТериАльная – ПРичины И Механизмы рАзвития”). Системные Гипертензии. 2010;(3):34–41.Chazova I. E., Fomin V. V., Razuvaeva M. A., Vigdorchik A. V. Epidemiological characteristics of resistant and uncontrolled arterial hypertension in the Russian Federation the all-Russian register of uncontrolled and resistant hypertension REGATA-PRIMA (Resistant arterial Hypertension – the causes and mechanisms of development). Systemic Hypertension. 2010;3:34-41.Coylewright M, Reckelhoff JF, Ouyang P. Menopause and Hypertension: An Age-Old Debate. Hypertension. 2008;51(4):952–9. DOI: 10.1161/HYPERTENSIONAHA.107.105742Coylewright M, Reckelhoff JF, Ouyang P. Menopause and Hypertension: An Age-Old Debate. Hypertension. 2008;51(4):952–9. DOI: 10.1161/HYPERTENSIONAHA.107.105742Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovascular Research. 2002;53(3):688–708. PMID: 11861040Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovascular Research. 2002;53(3):688–708. PMID: 11861040Bălan H, Popescu L. ‘Gender specifc medicine’: a focus on genderdifferences in hypertension. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne. 2014;52(3):129–41. PMID: 25509556Bălan H, Popescu L. ‘Gender specifc medicine’: a focus on genderdifferences in hypertension. Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne. 2014;52(3):129–41. PMID: 25509556Улубиева Е. А., Автандилов А. Г., Пухаева А. А., Либов И. А. Курение и менопауза. Структурно-функциональные изменения артерий у женщин. Проблемы женского здоровья. 2016;11(2):22– 7.Ulubieva E. A., Avtandilov A. G., Puhaeva A. A., Libov I. A. Smoking and menopause. Structural functional changes of the arteries in women. Problem of women health. 2016; 2(11):22-7.Giralt D, Domingues-Montanari S, Mendioroz M, Ortega L, Maisterra O, Perea-Gainza M et al. Te gender gap in stroke: a meta-analysis: Gender differences in ischemic stroke. Acta Neurologica Scandinavica. 2012;125(2):83–90. DOI: 10.1111/j.1600-0404.2011.01514.xGiralt D, Domingues-Montanari S, Mendioroz M, Ortega L, Maisterra O, Perea-Gainza M et al. Te gender gap in stroke: a meta-analysis: Gender differences in ischemic stroke. Acta Neurologica Scandinavica. 2012;125(2):83–90. DOI: 10.1111/j.1600-0404.2011.01514.xKouvari M, Panagiotakos DB, Chrysohoou C, Georgousopoulou E, Notara V, Tousoulis D et al. Gender-specifc, Lifestyle-related Factors and 10-year Cardiovascular Disease Risk; the ATICA and GREECS Cohort Studies. Current Vascular Pharmacology. 2018; DOI: 10.2174/1570161116666180608121720Kouvari M, Panagiotakos DB, Chrysohoou C, Georgousopoulou E, Notara V, Tousoulis D et al. Gender-specifc, Lifestyle-related Factors and 10-year Cardiovascular Disease Risk; the ATICA and GREECS Cohort Studies. Current Vascular Pharmacology. 2018; DOI: 10.2174/1570161116666180608121720Song S, Kim J, Kim J. Gender Differences in the Association between Dietary Patern and the Incidence of Hypertension in MiddleAged and Older Adults. Nutrients. 2018;10(2):252. DOI: 10.3390/nu10020252Song S, Kim J, Kim J. Gender Differences in the Association between Dietary Patern and the Incidence of Hypertension in MiddleAged and Older Adults. Nutrients. 2018;10(2):252. DOI: 10.3390/nu10020252Reckelhoff JF. Gender differences in hypertension: Current Opinion in Nephrology and Hypertension. 2018;1. DOI: 10.1097/MNH.0000000000000404Reckelhoff JF. Gender differences in hypertension: Current Opinion in Nephrology and Hypertension. 2018;1. DOI: 10.1097/MNH.0000000000000404Rosano GMC, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Terapy of the ESC: Figure 1. European Heart Journal. 2015;36(40):2677–80. DOI: 10.1093/eurheartj/ehv161Rosano GMC, Lewis B, Agewall S, Wassmann S, Vitale C, Schmidt H et al. Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Terapy of the ESC: Figure 1. European Heart Journal. 2015;36(40):2677–80. DOI: 10.1093/eurheartj/ehv161Scot PE, Unger EF, Jenkins MR, Southworth MR, McDowell T-Y, Geller RJ et al. Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs. Journal of the American College of Cardiology. 2018;71(18):1960–9. DOI: 10.1016/j.jacc.2018.02.070Scot PE, Unger EF, Jenkins MR, Southworth MR, McDowell T-Y, Geller RJ et al. Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs. Journal of the American College of Cardiology. 2018;71(18):1960–9. DOI: 10.1016/j.jacc.2018.02.070Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Te Lancet. 2002;359(9311):995– 1003. DOI: 10.1016/S0140-6736(02)08089-3Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Te Lancet. 2002;359(9311):995– 1003. DOI: 10.1016/S0140-6736(02)08089-3Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Te Lancet. 2004;363(9426):2022–31. DOI: 10.1016/S0140-6736(04)16451-9Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Te Lancet. 2004;363(9426):2022–31. DOI: 10.1016/S0140-6736(04)16451-9ALLHAT Ofcers and Coordinators for the ALLHAT Collaborative Research Group. Te Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Atack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: Te Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Atack Trial (ALLHAT). JAMA. 2002;288(23):2981–97. PMID: 12479763ALLHAT Ofcers and Coordinators for the ALLHAT Collaborative Research Group. Te Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Atack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: Te Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Atack Trial (ALLHAT). JAMA. 2002;288(23):2981–97. PMID: 12479763Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfeld M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Te Lancet. 2005;366(9489):895–906. DOI: 10.1016/S0140-6736(05)67185-1Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfeld M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Te Lancet. 2005;366(9489):895–906. DOI: 10.1016/S0140-6736(05)67185-1Zancheti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of fndings from the VALUE trial: Journal of Hypertension. 2006;24(11):2163–8. DOI: 10.1097/01.hjh.0000249692.96488.46Zancheti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of fndings from the VALUE trial: Journal of Hypertension. 2006;24(11):2163–8. DOI: 10.1097/01.hjh.0000249692.96488.46Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E et al. Effects of Losartan in Women with Hypertension and Lef Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study. Hypertension. 2008;51(4):1103– 8. DOI: 10.1161/HYPERTENSIONAHA.107.105296Os I, Franco V, Kjeldsen SE, Manhem K, Devereux RB, Gerdts E et al. Effects of Losartan in Women with Hypertension and Lef Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study. Hypertension. 2008;51(4):1103– 8. DOI: 10.1161/HYPERTENSIONAHA.107.105296Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal. 2008;29(21):2669–80. DOI: 10.1093/eurheartj/ehn427Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal. 2008;29(21):2669–80. DOI: 10.1093/eurheartj/ehn427Скибицкий В. В., Городецкая Е. В., Фендрикова А. В., Кудряшов Е. В. Гендерные особенности влияния комбинированной антигипертензивной терапии на структурно-функциональное состояние миокарда левого желудочка у больных артериальной гипертонией и ишемической болезнью сердца. Проблемы женского здоровья. 2015;10(1):10–9.Skibitskiy V. V., Gorodetskaya E. V., Fendrikova A. V., Kudryashov E. A. Gender features of influence combination antihypertensive therapy on structural functional state of lef ventricular myocardium in patients with arterial hypertension and coronary heart disease. Problem of women health. 2015;10(1):10-9.Denton KM, Hilliard LM, Tare M. Sex-Related Differences in Hypertension: Seek and Ye Shall Find. Hypertension. 2013;62(4):674–7. DOI: 10.1161/HYPERTENSIONAHA.113.00922Denton KM, Hilliard LM, Tare M. Sex-Related Differences in Hypertension: Seek and Ye Shall Find. Hypertension. 2013;62(4):674–7. DOI: 10.1161/HYPERTENSIONAHA.113.00922Глезер М. Г. Программа ПОТЕНЦИАЛ: использование фиксированной комбинации периндоприла А/амлодипина обеспечивает высокую приверженность к терапии, эффективное и безопасное снижение артериального давления у пациентов с ранее неэффективной комбинированной терапией. Кардиология. 2015;55(12):17–24.Glezer M. G. Te Use of Fixed Perindopril A/Amlodipine Combination Provides High Compliance to Terapy, Effective and Safe Arterial Pressure Lowering in Patients with Previous Inefferctive Terapy. Te POTENTIAL Program. Kardiologiia. 2015;55(12):17-24.Scherer PE. Adipose Tissue: From Lipid Storage Compartment to Endocrine Organ. Diabetes. 2006;55(6):1537–45. DOI: 10.2337/db060263Scherer PE. Adipose Tissue: From Lipid Storage Compartment to Endocrine Organ. Diabetes. 2006;55(6):1537–45. DOI: 10.2337/db060263Bermudez JA, Velásquez CM. Profle of free faty acids (FFA) in serum of young Colombians with obesity and metabolic syndrome. Archivos Latinoamericanos De Nutricion. 2014;64(4):248–57. PMID: 26336720Bermudez JA, Velásquez CM. Profle of free faty acids (FFA) in serum of young Colombians with obesity and metabolic syndrome. Archivos Latinoamericanos De Nutricion. 2014;64(4):248–57. PMID: 26336720Scheen AJ, Krzesinski JM. Which place for thiazide and thiazide-like diuretics in patients with type 2 diabetes? Revue Medicale De Liege. 2018;73(4):176–82. PMID: 29676870Scheen AJ, Krzesinski JM. Which place for thiazide and thiazide-like diuretics in patients with type 2 diabetes? Revue Medicale De Liege. 2018;73(4):176–82. PMID: 29676870Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database of Systematic Reviews. 2018; DOI: 10.1002/14651858.CD001841.pub3Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database of Systematic Reviews. 2018; DOI: 10.1002/14651858.CD001841.pub3Soldin OP, Matison DR. Sex Differences in Pharmacokinetics and Pharmacodynamics: Clinical Pharmacokinetics. 2009;48(3):143–57. DOI: 10.2165/00003088-200948030-00001Soldin OP, Matison DR. Sex Differences in Pharmacokinetics and Pharmacodynamics: Clinical Pharmacokinetics. 2009;48(3):143–57. DOI: 10.2165/00003088-200948030-00001Rydberg DM, Mejyr S, Loikas D, Schenck-Gustafsson K, von Euler M, Malmström RE. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. European Journal of Clinical Pharmacology. 2018;74(9):1165–73. DOI: 10.1007/s00228-018-2480-yRydberg DM, Mejyr S, Loikas D, Schenck-Gustafsson K, von Euler M, Malmström RE. Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs. European Journal of Clinical Pharmacology. 2018;74(9):1165–73. DOI: 10.1007/s00228-018-2480-y

The authors declare that there are no conflicts of interest present.